Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M
Multicenter, Randomized and OpenⅡb Clinical Trials to Evaluate the Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients Harbouring T790M Mutation
Sponsor: Allist Pharmaceuticals, Inc.
Terminated
Indications have been approved for marketing
Other terminated trials from Allist Pharmaceuticals, Inc.
More terminations from Allist Pharmaceuticals, Inc.
This PHASE2 trial investigates Advanced NSCLC Patients With T790M and is currently terminated or withdrawn. Allist Pharmaceuticals, Inc. leads this study, which shows 8 recorded versions since 2018 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
May 2025 — Present [monthly]
Terminated PHASE2
Status: Unknown → Terminated
-
Sep 2024 — May 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Oct 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE2
▶ Show 3 earlier versions
-
Feb 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Aug 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE2
Status: Not Yet Recruiting → Active Not Recruiting
-
Mar 2018 — Aug 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Allist Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .